Last edition
News about "HCQ as add-on therapy in type 2 diabetes"
Ipca Laboratories Ltd has received approval from the subject expert committee (SEC) at Central Drugs Standard Control Organisation (CDSCO) to conduct phase III study of antimalarial drug hydroxychloroquine (HCQ) as an add-on therapy in type 2 diabetes patients uncontrolled on metformin monotherapy
HCQ As Add-on Therapy In Type 2 Diabetes | 25/06/2021 | By Darshana | 236
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members